211 filings
Page 7 of 11
8-K
5fhkk8
21 Apr 20
Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab
8:31am
8-K
7ao17mu4b
11 Mar 20
Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
4:26pm
424B5
j413fkf1f oxin0omo23
21 Nov 19
Prospectus supplement for primary offering
8:31am
8-K
sjb60
20 Nov 19
Entry into a Material Definitive Agreement
4:50pm
424B5
cz5wt jrsdoj2om56i
19 Nov 19
Prospectus supplement for primary offering
5:26pm
8-K
5gijis4n1 i5
7 Nov 19
Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
4:45pm
8-K
begqz
8 Aug 19
Checkpoint Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
4:35pm
8-K
bsdz iqqq
12 Jun 19
Submission of Matters to a Vote of Security Holders
5:17pm
8-K
vzcrf ws5ub6
9 May 19
Checkpoint Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
5:13pm
8-K
9avbs7s2m7
1 May 19
Checkpoint Therapeutics Announces Positive Interim Clinical Results of Anti-PD-L1 Antibody Cosibelimab
7:45am
DEFA14A
a8lsh09ptjcc 8522
30 Apr 19
Additional proxy soliciting materials
6:34am
CT ORDER
i1ewv2 fjkf0
25 Apr 19
Confidential treatment order
5:01pm
8-K
2k07 n6wv
15 Mar 19
Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights
7:40am